Metformin Chemoprevention Against Pancreatic Adenocarcinoma In Patients With Type 2 Diabetes Mellitus: Results Of A Disease Simulation Model

Abstract

Sensitivity analyses eliminating T315I status from the weighting yielded similar results. ConClusions: Adjusted ponatinib efficacy outcomes in third-line CP-CML were similar to unadjusted, and efficacy was more than double that observed with bosutinib, irrespective of T315I mutation status. These results suggest that the higher efficacy observed is PACE (ponatinib) versus the bosutinib trial is not due to bias in patient selection.